The draft focuses on the optimal glycaemic targets for the prevention of micro- and macrovascular complications (unchanged from the previous SIGN 116 guidance) and the risks and benefits of glucose-lowering drugs and insulins. An updated treatment algorithm is also due to be published but is not yet available in the draft version.
SIGN is interested in the views of healthcare professionals regarding the comprehensiveness and accuracy of interpretation of the evidence base behind the guideline. Interested parties can access the draft at: http://www.sign.ac.uk/consultation/index.html
Feedback should be submitted before 12 pm on 26 May 2017.
